Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
IV solution, IV, Q3W, 350 mg/m2, until progression
Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
Oral, tablet, QD, until progression
Buenos Aires, Buenos Aires, Argentina